Systemic lupus erythematosus (SLE) is the most heterogeneous chronic autoimmune
disease. Biologic markers that reliably describe various aspects of SLE could be used to …

There is a high level of interest in the identification and validation of biomarkers that
precisely reflect specific aspects of systemic lupus erythematosus (SLE). Patients are hoping …

There is a longstanding and recently rejuvenated enthusiasm for biomarkers that precisely
and specifically reflect the pathophysiologic and clinical changes in systemic lupus …

The search for lupus biomarkers to diagnose, monitor, stratify, and predict individual
response to therapy is currently more intense than ever before. This effort is essential for …

Few biomarkers for systemic lupus erythematosus (SLE) have been validated and employed
for making clinical decisions. The lack of reliable, specific biomarkers for SLE hampers the …

SLE, a multisystem heterogeneous disease, is characterized by production of antibodies to
cellular components, with activation of both the innate and the adaptive immune system …

Systemic lupus erythematosus (SLE) is a complex and highly heterogeneous disease, which
affects multiple organs, including joints, skin, kidneys, heart, hematopoietic system, and …

The urgent need for lupus biomarkers was demonstrated in September 2011 during a
Workshop sponsored by the Food and Drug Administration: Potential Biomarkers Predictive …

Clinicians and representatives of academia, industry, the National Institutes of Health (NIH;
both intramural and extramural programs), and the Food and Drug Administration (FDA) met …

There are several autoimmune and rheumatic diseases affecting different organs of the
human body. Multiple sclerosis (MS) mainly affects brain, rheumatoid arthritis (RA) mainly …